Trinity Biotech PLC (NASDAQ:TRIB) Short Interest Up 439.6% in August

Trinity Biotech PLC (NASDAQ:TRIB) was the target of a significant growth in short interest in August. As of August 15th, there was short interest totaling 1,990,000 shares, agrowthof439.6% from the July 31st total of 368,800 shares. Based on an average daily volume of 4,970,000 shares, the short-interest ratio is currently 0.4 days. Approximately11.4% of the shares of the stock are sold short. Approximately11.4% of the shares of the stock are sold short. Based on an average daily volume of 4,970,000 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TRIB shares. Zacks Research upgraded Trinity Biotech to a “hold” rating in a research report on Monday, August 11th. Wall Street Zen began coverage on Trinity Biotech in a research note on Saturday, May 17th. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Trinity Biotech has a consensus rating of “Hold”.

Hedge Funds Weigh In On Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its position in Trinity Biotech PLC (NASDAQ:TRIB) by 16.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 437,910 shares of the company’s stock after buying an additional 62,800 shares during the period. Hunter Associates Investment Management LLC owned approximately 2.43% of Trinity Biotech worth $284,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 78.97% of the stock is currently owned by institutional investors.

Trinity Biotech Trading Down 4.1%

Shares of TRIB opened at $1.40 on Wednesday. The business’s fifty day simple moving average is $4.31 and its two-hundred day simple moving average is $3.71. Trinity Biotech has a 12 month low of $0.48 and a 12 month high of $3.44.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.